UroLift vs Rezūm for BPH: Symptom Relief, Sexual Effects and Recovery

01. UroLift vs Rezūm for BPH: Key Clinical Differences

What is the primary difference between UroLift and Rezūm?

The primary difference is the way each treatment changes the tissue surrounding the prostatic urethra.

UroLift, or prostatic urethral lift, is mechanical. Small permanent implants retract selected prostate tissue away from the urinary channel. The tissue remains alive and in place but is held farther from the urethral lumen.

Rezūm, or water-vapor thermal therapy, is ablative. Steam is injected into selected areas of prostate tissue. When that vapor condenses, it releases thermal energy, causing localized cell death. The treated tissue is then gradually resorbed by the body.

How are UroLift and Rezūm similar?

Both are designed to provide symptom relief with less perioperative burden than conventional transurethral surgery.

They share several practical characteristics:

• both can be performed without an abdominal incision;
• both may be performed in an outpatient setting;
• both generally preserve erectile function;
• both have favorable ejaculatory-function profiles compared with conventional TURP or standard HoLEP;
• both can reduce dependence on BPH medication in some patients;
• neither routinely provides tissue for pathological examination;
• and both have higher uncertainty about very long-term durability than established tissue-removing surgery.

Both are therefore most useful when their specific trade-offs match the patient’s anatomy and treatment priorities rather than simply because they are described as minimally invasive.

02. How Do UroLift and Rezūm Differ?

How quickly does each procedure begin to relieve urinary obstruction?

UroLift creates a mechanical opening during the procedure itself.

As implants retract lateral prostate tissue, the urethral lumen becomes wider immediately. Swelling and urinary irritation can still affect early symptoms, but the structural change does not depend on waiting for tissue to die and shrink.

Rezūm works differently.

Water vapor creates thermal injury during treatment, but the final reduction in prostate volume develops afterward. Early inflammation may initially cause urinary irritation or temporary worsening before tissue resorption begins.

For this reason, symptom improvement after Rezūm generally develops progressively over several weeks and may continue over the following months.

Which treatment provides greater symptom and flow improvement?

Both UroLift and Rezūm improve urinary symptom scores and quality of life.

A 2021 analysis compared the separate pivotal randomized trials for the two treatments. At three months, symptom-score improvement was similar: approximately 51% after Rezūm and 50% after UroLift.

At 24 and 36 months, that analysis found somewhat greater average International Prostate Symptom Score improvement after Rezūm.

Maximum urinary flow improved more after Rezūm at three months in the same analysis, but the difference between treatments was not significant from 12 through 36 months.

How does prostate anatomy affect the choice?

Prostate volume and the pattern of enlargement matter for both procedures.

The AUA evidence base for both treatments has traditionally centered on prostates around 30–80 g.

European guidance for UroLift is narrower, recommending it particularly for men with prostates below about 70 mL and no obstructing middle lobe.

Rezūm’s pivotal randomized study involved glands from 30–80 cc and allowed treatment of middle-lobe tissue at the physician’s discretion.

This gives water-vapor therapy an important anatomical difference: selected median-lobe enlargement can be directly treated.

The relationship between prostate shape and bladder-outlet obstruction is also explained in intravesical prostatic protrusion.

The actual gland size should be measured rather than estimated from symptoms. See How Is Prostate Volume Measured?

03. UroLift vs Rezūm: Recovery, Sexual Effects and Durability

Which procedure usually has the easier early recovery?

UroLift generally has the advantage in speed of early recovery.

Because it does not intentionally create thermal tissue necrosis, there is no required period of prostate-tissue resorption before its mechanical effect develops.

Post-procedure dysuria, hematuria, pelvic discomfort and urgency can occur, but symptoms are usually mild to moderate and temporary.

Catheterization is not required for every patient.

Rezūm creates a stronger local inflammatory response because tissue is deliberately thermally ablated.

Temporary dysuria, frequency, urgency, pelvic discomfort and worsening outlet symptoms can therefore be more noticeable during early recovery.

Temporary catheterization is also relatively common after Rezūm, particularly when swelling or baseline obstruction makes bladder emptying difficult.

A real-world academic-center comparison found more dysuria and non-clot urinary retention after Rezūm than after UroLift, although both treatments had broadly similar medium-term effectiveness.

Which procedure is better for preserving ejaculation?

Both procedures have favorable sexual-function profiles.

The five-year UroLift L.I.F.T. study reported stable sexual function without new sustained erectile or ejaculatory dysfunction attributed to treatment.

Five-year Rezūm trial data likewise reported no device- or procedure-related sexual dysfunction and no sustained new erectile dysfunction.

A comparison of the separate pivotal trials found a stronger improvement in validated ejaculatory-function scores after UroLift, although both treatments performed well in terms of sexual preservation.

This means UroLift may have a particular appeal for men who place a very high priority on ejaculatory preservation, but neither procedure should be described as guaranteeing that sexual function will never change.

Which procedure has the lower retreatment rate?

This question requires careful interpretation.

In the original pivotal trials, UroLift had a 13.6% surgical retreatment rate over five years, while Rezūm reported a 4.4% surgical retreatment rate over five years.

Those figures appear to favor Rezūm.

However, they come from different clinical trials, not from direct randomization between the two procedures.

A 2021 cross-trial analysis similarly found lower surgical retreatment with Rezūm at three years.

More recent real-world evidence makes the comparison less simple. A 2026 propensity-matched analysis of 3,697 patients found no statistically significant overall difference in three-year reintervention between Rezūm and UroLift after matching.

A separate large real-world analysis published in 2025 did find lower cumulative reintervention with Rezūm through five years.

The best interpretation is therefore that Rezūm may have a durability advantage in some datasets, but current evidence does not justify telling every patient that Rezūm will definitely last longer than UroLift.

04. When Does the Difference Between UroLift and Rezūm Matter Clinically?

Which patient priorities may favor UroLift?

UroLift may be particularly attractive when a patient places greater value on:

• rapid early recovery;
• avoiding thermal destruction of prostate tissue;
• minimizing postoperative catheter use;
• very strong preservation of ejaculatory function;
• and having anatomy that can be effectively opened using implant-based tissue retraction.

Its strongest guideline-supported role is in appropriately selected smaller or moderate-size glands without an obstructing middle lobe.

See the full UroLift for BPH guide for the individual procedure details.

Which patient priorities may favor Rezūm?

Rezūm may be particularly attractive when a patient prioritizes:

• avoiding a permanent implant;
• preserving erectile and ejaculatory function;
• treating suitable median-lobe tissue;
• accepting a slower recovery in exchange for actual tissue-volume reduction;
• and potentially reducing the probability of later surgical retreatment compared with some UroLift datasets.

The trade-off is that the inflammatory recovery phase can involve more temporary urinary discomfort and catheter use.

See the full Rezūm for BPH guide for the mechanism, recovery and long-term evidence.

When should one or both options be evaluated separately?

Neither UroLift nor Rezūm should be selected simply because a man has urinary symptoms and an enlarged prostate.

Lower urinary tract symptoms can arise from bladder dysfunction, urethral narrowing, neurological disease, infection and other causes.

Even within BPH, prostate volume does not directly measure the degree of outlet obstruction.

FBU explains these distinctions in Does Prostate Size Predict BPH Symptoms? and How Is BPH Diagnosed?

Men with severe obstruction, recurrent retention, significant complications, very large glands or a need for stronger objective decompression may be better served by a tissue-removing procedure.

Options such as TURP, HoLEP, Aquablation or other procedures may then enter the discussion.

What should patients ask before choosing between UroLift and Rezūm?

• What is my measured prostate volume?
• Is my prostate actually causing significant bladder-outlet obstruction?
• Do I have an obstructing median lobe?
• How much improvement in urinary flow should I realistically expect?
• How important is preserving ejaculation to me?
• Do I want to avoid a permanent implant?
• How likely am I to need a catheter after treatment?
• How long might urinary burning, urgency or frequency last?
• What are this clinician’s own retreatment rates for each procedure?
• Would a tissue-removing procedure provide more appropriate decompression?

The full range of surgical and minimally invasive choices is explained in BPH Surgery and Minimally Invasive Procedures.